Shanghai Fuxing Pharmaceutical (Group) Co., Ltd. ("Fosun", stock code 600196), founded in 1994, in August 1998 Shanghai Stock Exchange, is the pharmaceutical industry in China, leading listed companies.

Fosun market in 13 years, net profit rose 13.55 times the average annual compound growth rate of 24.26%. Sales, net assets, net profit, the stock market are among the forefront of China's pharmaceutical companies.

Fosun focus of modern biomedical health industry, to seize the rapidly growing Chinese pharmaceutical market and Chinese enterprises to enter the mainstream of the world pharmaceutical market of great opportunities to "brand, innovation, efficiency, globalization" for the business philosophy, and heavy industry consolidation to accelerate the implementation of product strategies, sound management, rapid development, has become the pharmaceutical drug development, manufacturing and distribution as the core, while in medical diagnostics, medical devices and healthcare services companies with leading market position and scale in research and innovation, marketing, merger integration, personnel development and other aspects of competitive advantage of large specialty pharmaceutical health industry groups.

Fosun focus on innovation and R & D, has a state-level enterprise technology center. In China, Fosun has been made in liver disease, diabetes, tuberculosis, clinical diagnostic products segment leader. In the global market, Fosun has become antimalarial leader in the field. Fosun investment Sinopharm successfully listed in Hong Kong in 2009, China's largest and the world's leading pharmaceutical distribution market listed companies. Currently, the Sinopharm has more than 10%market share, sales revenues exceeded the second, three combined. Pharmaceutical retail, pharmaceutical Fosun's National pharmacy retail brands, complex U.S. Pharmacy, Golden Elephant Pharmacy to continue in their respective regional market leadership and profitability of leading brands, with Shanghai, Beijing as the center for national development of the pharmaceutical retail landscape.

superior market performance to Fosun become the world's top business school case. Sustained and steady development of the Fosun to become China's listed companies in the benchmark, ranking the leading position in the industry; brand health in the pharmaceutical industry and capital markets are much trust.

Fosun to pursue sustainable development principles, the company's social responsibility, economic and ecological benefits as important as the location of place. Corporate citizen, has been incorporated into long-term development strategy. Fosun has been committed to public welfare, an active part in the development of China Guangcai actively assist the Chinese government's foreign aid, education, orphans and disabled assistance, disaster relief, and to invest billions of dollars.

future, Fosun will continue to promote human health mission, adhering to the "continuous innovation to share health" concept, to take "endogenous growth, expansion and extension-type integrated development" strategy development of means to further strengthen the leading position in China's pharmaceutical industry, while innovation strategy for the pilot, for the international and domestic markets, to create an internationally competitive health of the globalization of pharmaceutical companies.